Single‐Dose Tolerability and Pharmacokinetics of Onradivir in Chinese Patients with Hepatic Impairment and Healthy Matched Controls

2024-9-17

Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Budesonide Oral Suspension in Healthy Adult Participants: A Randomized Phase 1 Study

2024-9-12

Population Pharmacokinetics of Xeligekimab: An Anti‐IL‐17A Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis

2024-9-10

A Model‐Based Approach Supporting Abacavir/Dolutegravir/Lamivudine Fixed‐Dose Combination Approval in Children Living with HIV‐1

2024-9-5

Incidence of Acute Kidney Injury in Trough and AUC/MIC Vancomycin Dosing Strategies in a Large Tertiary Care Center: A Retrospective Cohort

2024-9-5

Efficacy of Low‐Dose Scopolamine and Palonosetron in Reducing Immediate Post‐Gastrointestinal Endoscopy Nausea and Vomiting: A Prospective, Randomized, Controlled Study

2024-9-3

Physiologically Based Pharmacokinetic Modeling of Vancomycin and its Comparison with Population Pharmacokinetic Model in Neonates

2024-9-3

Pharmacokinetics and Safety of Cilofexor and Firsocostat in Healthy Japanese and Non‐Japanese Participants

2024-8-30

Real‐World Evidence Application in Translational Medicine: Making Use of Prescription Claims to Inform Drug–Drug Interactions of a New Psoriasis Treatment

2024-8-28

In Vivo Activity of Intestinal P‐Glycoprotein and Hepatic Organic Anion Transporters Polypeptide in Pregnancy and Postpartum

2024-8-27

Reply to: Comment: Cerebrospinal Fluid Pharmacokinetics of Nicardipine Following Intrathecal Administration in Subarachnoid Hemorrhage Patients

2024-8-27

Issue Information

2024-8-27

Evaluation of Obesity‐Related Physiological Changes on Pantoprazole Clearance in Children Using a Population Pharmacokinetic Approach

2024-8-27

Correction to “The Association Between Concurrence of Infection and the Onset of Severe Eruption or Liver Injury in Patients Using Antipyretic Analgesics: A Matched, Nested Case‐Control Study”

2024-8-27

Prostatic Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime: Dosing Strategy for Bacterial Prostatitis

2024-8-26

Comment: Cerebrospinal Fluid Pharmacokinetics of Nicardipine Following Intrathecal Administration in Subarachnoid Hemorrhage Patients

2024-8-24

Simultaneously Predicting Pharmacokinetics of Loratadine and Desloratadine in Children Using a Whole‐Body Physiologically Based Pharmacokinetic Model

2024-8-22

First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of DS‐7011a, an Anti‐TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

2024-8-22

A Randomized, Parallel, Open‐Label, Single‐Dose and Multiple‐Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in China

2024-8-19

Population Pharmacokinetics (PopPK) Support for Pediatric Dosing of Biological Products

2024-8-16

Multiple‐dose pharmacokinetics of cenerimod and the effect of charcoal on its elimination

2024-8-14

Tracing the Evolution: A Comprehensive Bibliometric Analysis of Drug Interaction Clinical Studies

2024-8-14

Phase 1 Safety and Pharmacokinetics Study of TAVO101, an Anti‐Human Thymic Stromal Lymphopoietin Antibody for the Treatment of Allergic Inflammatory Conditions

2024-8-14

Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of SHR4640, a Selective Human Urate Transporter 1 Inhibitor

2024-8-14

Driving Efficiency: Leveraging Model‐Informed Approaches in 505(b)(2) Regulatory Actions

2024-8-9

Pharmacokinetics of Dexamethasone in Children and Adolescents with Obesity

2024-8-9

Safety, Tolerability, and Pharmacokinetics of Single Doses of Exidavnemab (BAN0805), an Anti‐α‐Synuclein Antibody, in Healthy Western, Caucasian, Japanese, and Han Chinese Adults

2024-8-6

Predict the Drug–Drug Interaction of a Novel PI3Kα/δ Inhibitor, TQ‐B3525, and Its Two Metabolites Using Physiologically Based Pharmacokinetic Modeling

2024-8-6

Redefining Statin Dosage Post‐Gastric Bypass: Insights from a Population Pharmacokinetics–Pharmacodynamics Link Approach

2024-8-5

Clinical Characteristics of Moxifloxacin‐Related Arrhythmias and Development of a Predictive Nomogram: A Case Control Study

2024-8-2

Physiologically Based Pharmacokinetic Modeling of Vancomycin in Critically Ill Neonates: Assessing the Impact of Pathophysiological Changes

2024-8-2

Influence of Dapagliflozin Dosing on Low‐Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus: A Systematic Literature Review and Meta‐Analysis

2024-8-1

Effects of Food, Gastric Acid Reduction, and Strong CYP3A Induction on the Pharmacokinetics of Tasurgratinib, a Novel Selective Fibroblast Growth Factor Receptor Inhibitor

2024-8-1

Population Pharmacokinetics and Loading Dose Optimization of Intravenous Valproic Acid in Hospitalized Thai Patients

2024-7-29

Issue Information

2024-7-28

A Model‐Informed Drug Development Approach Supporting the Approval of an Unstudied Valbenazine Dose for Patients With Tardive Dyskinesia

2024-7-25

Population Pharmacokinetic Modeling of Adavosertib (AZD1775) in Patients with Solid Tumors

2024-7-19

Population Pharmacokinetic Analysis of Dolutegravir in Treatment‐Experienced Adults Living with HIV‐1

2024-7-16

Safety, Pharmacokinetics, and Pharmacodynamics of the New Aldose Reductase Inhibitor Govorestat (AT‐007) After a Single and Multiple Doses in Participants in a Phase 1/2 Study

2024-7-10

Exposure–Response Modeling in Adults and Adolescents With Schizophrenia to Support the Extrapolation of Brexpiprazole Efficacy to Adolescents

2024-7-8

Labetalol Dosing in Pregnancy: PBPK/PD and CYP2C19 Polymorphisms

2024-7-8

Comparison of Anti‐Hepatitis A Antibody Pharmacokinetics in Healthy Australian Subjects Receiving Standard or Weight‐Based Dosing of Polyvalent Immunoglobulin

2024-7-5

ACCP Position Statement on Unregulated Psychotropic Products

2024-7-2

Pharmacokinetics of Human Plasma‐Derived Antithrombin in Pediatric Patients Supported on Extracorporeal Membrane Oxygenation

2024-7-2

Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists

2024-6-26

Issue Information

2024-6-25

A big thank you and a warm welcome

2024-6-25